Skip to main content
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD. logo

GUIZHOU SANLI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 603439 ISIN · CNE1000040B4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 904 across all filing types
Latest filing 2026-05-20 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 603439

About GUIZHOU SANLI PHARMACEUTICAL CO.,LTD.

https://www.gz-sanli.com/

Guizhou Sanli Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of traditional Chinese medicine (TCM) preparations. The company focuses on respiratory and throat health, with its flagship product line being the Kaihoujian Spray series, available in both pediatric and adult formulations. These products are primarily used for treating inflammatory conditions of the throat and oral cavity. The company maintains a strong market position in the pediatric TCM segment through its specialized spray delivery systems and proprietary formulations. Its operations encompass the entire value chain from pharmaceutical manufacturing to marketing and sales, emphasizing the modernization of traditional herbal remedies.

Recent filings

Filing Released Lang Actions
贵州三力制药股份有限公司关于回购注销部分限制性股票减资暨通知债权人的公告
Transaction in Own Shares Classification · 90% confidence The document is a formal announcement by the company regarding the repurchase (buyback) and cancellation of its own restricted shares and associated capital reduction, including creditor notification procedures. This is a classic share repurchase/cancellation disclosure, matching the definition of “Transaction in Own Shares” (POS).
2026-05-20 Chinese
贵州三力制药股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official announcement of the 2025 annual general meeting (AGM) resolutions, detailing attendance, each proposal voted on, and voting results. It is not the full AGM presentation or annual report itself but the formal declaration of voting outcomes from the shareholders’ meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-20 Chinese
北京市中伦律师事务所关于贵州三力制药股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 67% confidence The document is a legal opinion letter (“法律意见书”) issued by Zhong Lun Law Firm regarding the procedural legality and voting outcomes of the 2025 Annual General Meeting (AGM) of Guizhou Sanli Pharmaceutical Co., Ltd. It is not the AGM materials themselves nor the formal announcement of resolutions (e.g., the company’s stock exchange filing of voting results), but rather a law firm certification of the meeting’s convening procedures and voting results. It does not contain substantive financial statements, proxy materials, or serve as a direct disclosure of the AGM results by the company. Consequently, it does not map to any specific filing type such as AGM materials, proxy statements, or a direct voting results announcement. It is best categorized under the general catchall “Regulatory Filings” (RNS).
2026-05-20 Chinese
贵州三力制药股份有限公司2025年年度股东会会议材料
AGM Information Classification · 91% confidence The document is the full set of “2025年年度股东会会议材料” for贵州三力制药股份有限公司 – i.e., the materials and presentations provided to shareholders at the Annual General Meeting (AGM). It includes the meeting notice, agenda, board work report, profit distribution proposal, staffing and share issuance proposals, and other AGM resolutions. It is not a standalone annual report or earnings preview but the actual AGM meeting pack. Therefore, it falls under AGM Information (Code: AGM-R).
2026-05-12 Chinese
贵州三力制药股份有限公司关于2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会召开情况的公告
Call Transcript Classification · 85% confidence The document is an announcement of the company’s 2025 performance explanation meeting (业绩说明会) held on May 11, 2026, conducted online with investor Q&A. It contains the questions posed by investors and the company’s responses, i.e., a transcript of an investor call/meeting. This matches the definition of a Call Transcript (CT). It is not a simple release of financial highlights (ER), nor a report publication notice (RPA), but the full text Q&A record of an earnings-related conference-style meeting.
2026-05-12 Chinese
贵州三力制药股份有限公司关于变更注册资本和经营范围并修订《公司章程》的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the board of directors of Guizhou Sanli Pharmaceutical Co., Ltd. regarding changes to the company's registered capital, business scope, and amendments to the company's articles of association (company charter). It details board meeting resolutions about share repurchases and cancellations, changes in registered capital, and revisions to the company's business scope and articles. The document is a formal public announcement of these corporate governance and capital structure changes, not a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document length is about 2501 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories like capital changes (SHA) or management changes (MANG). Although it involves capital changes, the primary focus is on announcing board resolutions and amendments to the articles, which is typical for RNS filings in Chinese regulatory practice. Hence, the classification is RNS with high confidence.
2026-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.